COMMUNIQUÉS West-GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

04/11/2024 - 22:30

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November: Guggenheim [...]

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

04/11/2024 - 22:30

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced [...]

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04/11/2024 - 22:36

Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024 AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024 Libervant® (diazepam) Buccal Film for [...]

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

04/11/2024 - 22:39

- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 [...]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/11/2024 - 22:44

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Nyxoah Nomme John Landry au Poste de Chief Financial Officer

04/11/2024 - 22:45

Nyxoah Nomme John Landry au Poste de Chief Financial Officer L'actuel CFO, Loïc Moreau, nommé au poste de Président International Mont-Saint-Guibert, Belgium – 4 Novembre 2024, 22h45 CET / 16h45 ET – Nyxoah SA (Euronext [...]

Nyxoah Appoints John Landry as Chief Financial Officer

04/11/2024 - 22:45

Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA ( [...]

Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares

04/11/2024 - 17:00

Company announcement no. 10 - 24 4 November 2024 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 [...]

bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada

04/11/2024 - 18:00

bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market The INSTI Hepatitis C (HCV) Antibody Test is authorized by Health Canada for immediate entry [...]

Informations relatives au nombre total de droits de vote et d’actions composant le capital

04/11/2024 - 18:00

Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée [...]

PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis

04/11/2024 - 18:00

GLORIA, 1 ère étude mondiale de phagothérapie de phase II dans le traitement des infections ostéo-articulaires sur prothèses (PJI) liées à Staphylococcus aureus Protocole clinique également en cours de soumission auprès [...]

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

04/11/2024 - 18:00

GLORIA, the world's 1 st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureus The clinical protocol also being submitted to the European health authorities [...]

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche’s Phase III Itovebi Breast Cancer Trial

04/11/2024 - 18:28

PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA’s approval of Inavolisib in the U.S. on October 10, 2024. [...]

Grant of Warrants

04/11/2024 - 18:44

4 November 2024 Announcement no. 21 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, November 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has [...]

Sienna Announces Change of timing to Third Quarter 2024 Conference Call

04/11/2024 - 19:00

MARKHAM, Ontario, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a change in the timing of its upcoming 2024 third quarter conference call with the [...]

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

04/11/2024 - 14:00

CARSON CITY, Nev., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and [...]

Sofwave to Participate in Stifel 2024 Healthcare Conference

04/11/2024 - 14:00

SAN CLEMENTE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, [...]

Avalyn to Participate in Multiple Upcoming Investor Conferences

04/11/2024 - 14:00

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, [...]

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

04/11/2024 - 14:00

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) [...]